PharmaFocus Today – Page 156 – media

Mindray Medical Ranks as one of the Best Brand in China

On September 3rd, Interbrand, a global brand strategy management consulting and design company, released the “2024 China’s Best Brands Ranking”. Mindray Medical was selected and maintained a strong upward trend for the second consecutive year, ranking 34th on the list with a brand value of 11.541 billion yuan, an increase of 18% compared to last year. Under the dual tests of economic cycles and market competition, the total value of the brands listed in the “2024 China’s Best Brands Ranking” maintained a slight increase, reaching 3371.26 billion yuan, showing an overall stable trend. Among them, over 60% of brands have achieved value growth, demonstrating strong brand resilience and innovation drive, including Mindray Medical. It should be emphasized that Mindray Medical is also the top ranked medical device brand on this list. So, what exactly did Mindray Medical rely on to achieve this result? In the process of promoting the upward ...
- Source: drugdu
- 245
- September 6, 2024
Two innovative medical devices have been approved for market launch

On September 3rd, the National Medical Products Administration announced that it has recently approved the registration applications for two innovative products, the “Navigation Positioning Microwave Ablation System” of True Health (Zhuhai) Medical Technology Co., Ltd. (hereinafter referred to as “True Health Medical”) and the “Hepatitis B Virus Surface Antigen (HBsAg) Detection Kit (Chemiluminescence Method)” of Fuji Ruibiou Co., Ltd. (hereinafter referred to as “Fuji Ruibiou”). True Health Medical: International First Product Founded in 2018, True Health Medical is a national high-tech enterprise specializing in the research and production services of surgical robots. Based on artificial intelligence technology, it integrates intelligent robot systems into the diagnosis and treatment process through the close integration of industry, academia, research, and medicine, achieving a comprehensive medical technology system with precise puncture of soft tissue lesions throughout the body as a diagnostic and treatment method. Precise puncture is a means to deliver minimally invasive treatment ...
- Source: drugdu
- 270
- September 6, 2024
Zhifei Biological’s 23-valent Pneumococcal Vaccine Price Reduction of Nearly 30%, Another Vaccine Field Will Be Involved in the “Price War”?

September 3, Jilin Province Public Resources Trading Center issued a document that will Zhifei Biological 23-valent pneumococcal polysaccharide vaccine from the original 298/branch down to 209 yuan/branch, down 29.87%. The following day, the Jiangsu Provincial Public Resources Trading Center issued a notice that also reduced the vaccine from 298/branch to 209 yuan/branch. At the end of August last year, Zhifei Biological’s 23-valent pneumococcal polysaccharide vaccine was formally approved for marketing in China for the prevention of infectious diseases caused by pneumococcus bacteria in children aged 2 years and above and adults. According to the half-year report of Zhifei Biological 2024, the approved and issued volume of its 23-valent pneumonia vaccine was 160,000 doses from January to June this year. During the same period, the approved and issued volume of Merck Sharp & Dohme’s 23-valent pneumonia vaccine, for which Zhifei Bio is the agent, amounted to 845,000 units, a year-on-year increase ...
- Source: drugdu
- 288
- September 6, 2024
The victory of tens of billions of dollars, the revelation of the rise of the new vaccine elite

Before the new crown vaccine, Pfizer’s 13-valent pneumococcal vaccine was the world’s “king of vaccines”, with global sales of nearly 6 billion US dollars in 2018, far exceeding the second-place 9-valent HPV vaccine (3.15 billion US dollars). No one wants to miss such a big market. While domestic companies are still rolling up the 13-valent pneumococcal vaccine (PCV13), Vaxcyte is rolling up the price type upgrade. VAX-24 is a vaccine covering 24 virus types, while VAX-31 has rolled up 31 types. Of course, the 13-valent pneumococcal vaccine has brought epoch-making changes to the prevention of pneumonia. However, while the popularity of PCV13 has greatly increased, it has also brought new troubles: the replacement of virus types. Since the introduction of PCV13, the incidence of diseases caused by the serotypes included in the vaccine has decreased. However, there is a phenomenon called serotype replacement, that is, after widespread vaccination, the incremental ...
- Source: drugdu
- 300
- September 6, 2024
AstraZeneca China’s structure will be adjusted

According to various sources in the industry, AstraZeneca China’s biopharmaceutical business BBU and omnichannel business unit structure will undergo a series of adjustments on October 1 this year. AstraZeneca China’s biopharmaceutical business and omnichannel business unit will be officially merged to form a new AstraZeneca China biopharmaceutical business (BBU). Merge the respiratory inhalation business unit, respiratory atomization business unit and digestive business unit to form the respiratory digestive business unit; merge the biologics business unit, vaccines and immunotherapy, and autoimmune business unit; merge the biologics business unit, vaccines and immunotherapy, and autoimmune business unit to form the respiratory and autoimmune biopharmaceuticals, vaccines and immunotherapy business units. According to incomplete statistics, this is at least the third adjustment of AstraZeneca China this year. “Adjustment” seems to be the key to AstraZeneca China’s performance development. AstraZeneca once said that the new map will add momentum to the long-term development of its business. ...
- Source: drugdu
- 390
- September 6, 2024
As a new upstart in the imaging industry, is its billion-dollar halo no longer there?

Recently, United Imaging Healthcare released its 2024 semi-annual report. In the first half of the year, United Imaging Healthcare’s revenue was 5.333 billion yuan, a year-on-year increase of 1.18%; it achieved a net profit attributable to the parent of 950 million yuan, a year-on-year increase of 1.33%; and a net profit attributable to the parent of 798 million yuan, a year-on-year increase of 1.39%. In the semi-annual report, the growth of United Imaging Healthcare slowed down, and based on this, the stock price has been falling. Now that the market value of United Imaging Healthcare is not guaranteed, how can the upstart break through? Founded in 2011, United Imaging Healthcare is committed to providing global customers with a full range of independently developed high-performance medical imaging diagnostic and treatment equipment, life science instruments, and innovative solutions covering the entire chain of “basic research-clinical research-medical transformation”. Since its listing on the ...
- Source: drugdu
- 243
- September 6, 2024
Edge Medical Releases Remote Surgery System

The 18th Annual Meeting of Chinese Hospital Directors was grandly held in Wuhan, Hubei from August 30th to September 1st. During the grand event, Edge Medical® Heavy Release of Edge Cloud ® The remote surgery system has been fully launched, and the “Thousand Medical Alliance Membership Program” has been fully launched to build a new intelligent remote surgery network platform with real-time multi-point interconnection, fully demonstrating the exclusive remote technology advantages of low latency, high fidelity, strong guarantee, and cloud interconnection. Continuously leading remote surgery, setting a historical record Remote surgery breaks through the limitations of space on surgical procedures, allowing high-quality medical resources and advanced surgical techniques from central cities to be projected in real-time to remote areas. It has important significance in alleviating uneven distribution of medical resources and promoting the sharing of advanced surgical technologies. In recent years, Edge Medical® Jointly with the General Hospital of the ...
- Source: drugdu
- 345
- September 5, 2024
Growth of United Imaging Healthcare has Slowed Down, Leading to a Continuous Decline in its Stock Price

Recently, Shanghai United Imaging Healthcare Co., Ltd. (also known as, United Imaging Healthcare) released its 2024 semi annual report, with a revenue of 5.333 billion yuan in the first half of the year, a year-on-year increase of 1.18%; Realize a net profit attributable to the parent company of 950 million yuan, a year-on-year increase of 1.33%; Deducting non attributable net profit of 798 million yuan, a year-on-year increase of 1.39%. The growth of Zhonglian Film Medical has slowed down in the semi annual report, leading to a continuous decline in its stock price. Now that the market value of United Imaging Healthcare is not guaranteed at billions, how can the new rich break through the situation? CT business is sluggish, with a market value of billions falling Founded in 2011, United Imaging Healthcare is committed to providing global customers with a full range of independently developed high-performance medical imaging diagnosis ...
- Source: drugdu
- 376
- September 5, 2024
JCI | Zhu Yingjie’s team from Shenzhen Advanced Institute reveals a new central target of GLP-1R agonist, a “weight loss drug”

Obesity, as one of the top ten chronic diseases worldwide, has a research history of over a century in the field of weight loss drugs. After 2014, glucagon like peptide-1 (GLP-1) receptor agonists emerged as a new force, far surpassing other weight loss drugs in terms of efficacy and safety, and also driving the development and marketing of weight loss drugs. GLP-1, as an intestinal insulinotropic hormone, is generated by the post-translational cleavage of pre glucagon encoded by the pre glucagon gene (GCG). It is mainly secreted by intestinal L cells and a portion of neurons in the solitary tract nucleus (NTS) of the brainstem. The action of GLP-1 is mediated by the GLP-1 receptor (GLP-1 R) and is widely distributed in the peripheral and central nervous systems. Liraglutide is a short acting GLP-1 receptor agonist that acts on the central nervous system to reduce appetite and slow gastric emptying. ...
- Source: drugdu
- 198
- September 5, 2024
The Lancet reports that semaglutide has the potential to be used in heart failure patients

Recently, The Lancet published a new centralized, participant level analysis of heart failure patients with mild reduced ejection fraction or preserved ejection fraction (HFpEF) from four randomized placebo-controlled trials (2.4 mg for SELECT, STEP-HFpEF, STEP-HFpEF DM; 1.0 mg/d). picture According to analysis, semaglutide reduced the composite risk of cardiovascular (CV) death or worsening heart failure (HF) events by 31%, with incidence rates of 5.4% in the semaglutide group and 7.5% in the placebo group (HR 0.69; 95% CI 0.53-0.89; P=0.0045). semaglutide also reduced the risk of HF worsening by 41% (2.8% vs. placebo 4.7%; HR 0.59 (95% CI 0.41-0.82), p=0.0019). Simeglutide had no significant effect on the incidence of CV mortality (3.1% in the Simeglutide group and 3.7% in the placebo group). Hr 0.82 (95% CI 0.57-1.16), p=0.25) The statistical analysis did not adjust for multiplicity, and the hazard ratio should not be used to infer definitive treatment efficacy. In ...
- Source: drugdu
- 145
- September 5, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.